By 2045, an astounding 736 million people could be living with diabetes1. Given the devastating human and economic cost that diabetes and its complications have on individuals, families and communities, this growth is simply unsustainable2.
We must change the trajectory of the rise in diabetes – and that means setting a bold ambition that no more than 1 in 10 adults globally has the disease.
To achieve this will require ambitious action on the biggest modifiable risk factor for diabetes – obesity: we must reduce obesity by 25% globally between now and 2045. If we do that, we will bend the curve on the huge rise in diabetes prevalence, and prevent an extra 111 million people developing the disease.
Cities Changing Diabetes was launched in 2014 by Novo Nordisk, University College London and the Steno Diabetes Center with the belief that the growing prevalence of diabetes is not inevitable. In collaboration with cities around the world, we have established new approaches that help communities understand their unique set of diabetes challenges, identify areas and populations at greatest risk, and design targeted interventions that can put change in motion.
No organisation can solve the diabetes challenge alone. A first-of-its-kind platform, Cities Changing diabetes is built on public-private partnerships between businesses, city leaders and planners, architects, healthcare professionals, academics, diabetes associations, health insurers, community leaders and others with a stake in halting the rise in urban diabetes. Today the programme has more than 100 cross-disciplinary, cross-sector partners around the world.
Only together, can we fight the rise of urban diabetes.
1. Cities Changing Diabetes. Diabetes Projection Model, Global. Data on file. Novo Nordisk. In: Incentive, ed. Holte, Denmark 2017.
2. WHO. Global report on diabetes. World Health Organization; 2016.